Safety and Preliminary Efficacy of Intranasal Insulin for Cognitive Impairment in Parkinson Disease and Multiple System Atrophy 1.0

File: <base>/Data_Dictionary.csv (1,078 bytes)
variablevariable_descriptionunitsexample_1example_2
Study NumberThe subject identifier45
IversusPInsulin vs Placebo0=Placebo, 1=Insulin01
AgeAgeYears5371
GenderGender1=Man. 2=Woman21
EtnicityEtnicityWhiteAfrican American
SmokingSmoking (Yes/No)0=No, 1=Yes00
Height (in)HeightInches6768
WeightWeightPounds155157
BMIBody Mass Indexkg/m224.323.9
DiseasePD=Parkinson DiseasePDPD
Disease DurationDisease DurationYears517
SBPSystolic Blood PressuremmHg113114
DBPDiastolic Blood PressuremmHg6974
HRHeart ratebeats/min7062
Walk-DurationWalk Durationseconds3.843.37
Walk-NoStepsNumber of steps#87
AverStride (in)Average Stride Length (Walk distance/Number of steps)Inches1821
MOCAThe Montreal Cognitive Assessment2826
GlucoseSerum glucosemg/dL9883
Gait Speed Gait speedm/s1.1363636361.567398119
BDIThe Beck Depression Inventory156
F#wordsWords starting with letter F#1116
A#wordsWords starting with letter A#1112
S#wordsWords starting with letter S#129
FASVerbal Fluncy Test3437